Coherus Oncology Inc
Coherus Oncology Inc (CHRS) Covered Calls
Coherus Oncology Inc trades in the Biotechnology industry with an IV Rank of 98.02%, high versus the past year. CHRS's highest covered call setup is the $1.00 strike expiring May 21, 2027, sorted by theoretical annualized return. It's 88.68% out of the money with 189 days to expiration, a 98.11% return until expiration, and a 189.48% theoretical annualized return. Across the setups shown, annualized returns run from 189.48% to 189.48% at strikes between $1.00 and $1.00, with 189 to 189 days to expiration, as of Nov 13, 2026.
Read more
Running CHRS covered calls helps you generate income from Coherus Oncology Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CHRS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If CHRS stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CHRS covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CHRS covered call is worth writing.
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors.
| 2027-05-21 | 189 | 1.00 | 88.68 | 0.05 | 0.35 | 52.00 | 98.11 | 189.48 | -9.43 | +0.61 | 131 | 0.30 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank98.02% High
- Market cap (M$)78
- 52 weeks high-80.53%
- 52 weeks low2.00%
- Analyst recommendationStrong Buy
1.00 - Target price$7.25
1321.57% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-09
- P/E—
- Future P/E—
- EPS (ttm)-0.97
- EPS growth next 5 years34.25%
As of Nov 16, 2026